AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

VANCOUVER, British Columbia -- AbCellera (Nasdaq: ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application (CTA) for ABCL575, an investigational antibody antagonist targeting OX40 ligand (OX40L) that is being developed for the treatment of moderate-to-severe atopic dermatitis (AD), with potential applications to other inflammatory and autoimmune conditions.

Health Canada Greenlights AbCellera's Novel Antibody Trial for Chronic Skin Disease Treatment

New antibody therapy ABCL575 targets OX40L for moderate-to-severe atopic dermatitis. Phase 1 trial launching Q3 2025. Learn trial specifics.